Savara (SVRA) Current Deferred Revenue (2018 - 2020)

Savara (SVRA) posted quarterly Current Deferred Revenue of $243000.0 for Q2 2020, up 2.1% quarter-over-quarter from $238000.0 in Q1 2020.

Savara (SVRA) Current Deferred Revenue (2018 - 2020) Analysis & Trends

Savara (SVRA) has reported Current Deferred Revenue for 3 consecutive years, with $243000.0 the latest figure, recorded in Q2 2020.

In Q2 2020, Current Deferred Revenue changed N/A year-over-year to $243000.0; the TTM figure through Jun 2020 stood at $243000.0 (changed N/A YoY), while the FY2018 annual figure was $250000.0, changed N/A from the prior year.
Current Deferred Revenue grew to $243000.0 in Q2 2020 per SVRA's latest filing, from $238000.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $250000.0 in Q4 2018 and bottomed at $238000.0 in Q1 2020.
Historically, Current Deferred Revenue has averaged $243250.0 across 3 years, with a median of $242500.0 in 2019.
On a YoY basis, Current Deferred Revenue climbed as much as 1.65% in 2020 and fell as far as 1.65% in 2020.
Savara's Current Deferred Revenue stood at $250000.0 in 2018, then dropped by 3.2% to $242000.0 in 2019, then rose by 0.41% to $243000.0 in 2020.
Business Quant data shows SVRA's Current Deferred Revenue at $243000.0 in Q2 2020, $238000.0 in Q1 2020, and $242000.0 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Savara	1.11 Bn	1.11 Bn	-

Download Data